Two Decades of (Mostly) Disappointments in Definitive Chemoradiation for Stage III Non-Small Cell Lung Cancer

John H Park
Additional contact information
John H Park: Kansas City VA Medical Center, USA

Cancer Therapy & Oncology International Journal, 2018, vol. 9, issue 5, 13-16

Abstract: The past two decades have little to show in the progress of definitive chemoradiation for stage III lung cancer patients. Radiation dose escalation, elective nodal irradiation, prophylactic cranial irradiation, and proton therapy have not shown to improve outcomes. The addition of surgery to the backbone of concurrent chemoradiation has also shown no benefit, except possibly in patients who can undergo a lobectomy. Consolidative chemotherapy, adjuvant gefitinib, induction chemotherapy, pemetrexed for non-squamous histologies, and the addition of cetuximab have also all failed in terms of systemic therapy. Progress has been made only recently with the addition of adjuvant durvalumab, a PD-L1 inhibitor, which significantly improved outcomes in this population and now is part of the standard of care.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555780.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555780.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:9:y:2018:i:5:p:13-16

DOI: 10.19080/CTOIJ.2018.09.555780

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().